These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34821881)

  • 1. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma.
    Slatnick LR; Jimeno A; Gore L; Macy ME
    Drugs Today (Barc); 2021 Nov; 57(11):677-688. PubMed ID: 34821881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naxitamab: First Approval.
    Markham A
    Drugs; 2021 Feb; 81(2):291-296. PubMed ID: 33616889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.
    Castañeda A; Gorostegui M; Miralles SL; Chamizo A; Patiño SC; Flores MA; Garraus M; Lazaro JJ; Santa-Maria V; Varo A; Muñoz JP; Mora J
    ESMO Open; 2022 Apr; 7(2):100462. PubMed ID: 35397431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
    Mora J; Castañeda A; Gorostegui M; Santa-María V; Garraus M; Muñoz JP; Varo A; Perez-Jaume S; Mañe S
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29121. PubMed ID: 34022112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
    Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
    Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital.
    Trovillion EM; Michael M; Jordan CC; Brown L; Phillips K; Oesterheld J; Saulnier-Sholler G
    Cancer Med; 2024 Feb; 13(3):e7045. PubMed ID: 38396377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
    Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
    JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.
    Mora J; Chan GC; Morgenstern DA; Nysom K; Bear MK; Tornøe K; Kushner BH
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1627. PubMed ID: 35579862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
    Muñoz JP; Larrosa C; Chamorro S; Perez-Jaume S; Simao M; Sanchez-Sierra N; Varo A; Gorostegui M; Castañeda A; Garraus M; Lopez-Miralles S; Mora J
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial Response to Naxitamab for Brain Metastasis in Neuroblastoma.
    Onyeukwu C; Williams A; Seyboth B; Muñoz L; Scaria G; Kent P
    J Pediatr Hematol Oncol; 2024 Mar; 46(2):e188-e190. PubMed ID: 38189408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance.
    Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S
    Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma.
    Cabral J; Fernandez EI; Toy B; Secola R
    Paediatr Drugs; 2023 Jan; 25(1):13-25. PubMed ID: 36434427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine.
    Galassi L; Rossi M; Lodeserto P; Lenzi M; Borsetti F; Voltattorni M; Farruggia G; Blasi P; Orienti I
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy with anti-G
    Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
    Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus.
    Nysom K; Morad AG; Rafael MS; Zier J; Marachelian A; Watt T; Morgenstern DA
    Pediatr Blood Cancer; 2023 May; 70(5):e30217. PubMed ID: 36772891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
    Ploessl C; Pan A; Maples KT; Lowe DK
    Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
    N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
    Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
    Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.